Advertisement
Advertisement
U.S. markets close in 1 hour 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Decibel Therapeutics, Inc. (DBTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.35000.0000 (0.00%)
As of 02:21PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.3500
Open2.4000
Bid2.3500 x 800
Ask2.3900 x 800
Day's Range2.2600 - 2.4800
52 Week Range1.8310 - 9.7500
Volume31,264
Avg. Volume63,967
Market Cap58.667M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.2030
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DBTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Decibel Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

    BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T

  • GlobeNewswire

    Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

    - Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program – - New preclinical data presented at the 45th Annual Association for Research in Otolaryngology Conference (ARO) supporting DB-OTO and emphasizing platform focus on cell-selective transgene expression – - Preclinical data to be presented at the Americ

  • GlobeNewswire

    Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

    BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held virtually and in Washington D.C. May 15-19, 2022. The Company will present on its lead investigational gene therapy, DB-OTO, being developed to res

Advertisement
Advertisement